Angiotensin II mediates urotensin II expression by hypoxia in cultured cardiac fibroblast

European Journal of Clinical Investigation

Volumn 42, Issue 1, 2012, Pages 17-26

  Shyu, Kou Gi ^a,b   Wang, Bao Wei ^a   Chen, Wei Jan ^c   Kuan, Peiliang ^a   Lin, Chiu Mei ^a,b  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Cytokine; Fibrosis; Hypoxia; Reactive oxygen species; Urotensin II

Indexed keywords

ACETYLCYSTEINE; ANGIOTENSIN II; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; LOSARTAN; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; UROTENSIN II;

ANIMAL CELL; ARTICLE; CELL HYPOXIA; COMPARATIVE STUDY; CONTROLLED STUDY; FIBROBLAST; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT;

ANALYSIS OF VARIANCE; ANGIOTENSIN II; ANIMALS; ANOXIA; BLOTTING, WESTERN; CELL CULTURE TECHNIQUES; CELLS, CULTURED; COLLAGEN TYPE I; FIBROBLASTS; HUMANS; MALE; MODELS, ANIMAL; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES; REAL-TIME POLYMERASE CHAIN REACTION; UROTENSINS; VASOCONSTRICTOR AGENTS;

EID: 83155181701     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2011.02549.x     Document Type: Article

References (34)

1. Sutton MGSJ, Sharpe N. Left ventricular remodeling after myocardial infarction. Pathophysiology and therapy. Circulation 2000;101:2981-8.
2. Ames RS, Sarau HM, Chambers JK, Willette RN, Aiyar NV, Romanic AM et al. Human urotensin II is a potent vasoconstrictor and agonists for the orphan receptor GPR14. Nature 1999;401:282-6.
3. Zhu YC, Zhu YZ, Moore PK. The role of urotensin II in cardiovascular and renal physiology and diseases. Br J Pharmacol 2006;148:884-901.
4. Papadopoulos O, Bousette N, Glaid A. Urotensin II and cardiovascular remodeling. Peptides 2008;29:764-9.
5. Chen YL, Liu JC, Loh SH, Chen CH, Hong CY, Chen JJ et al. Involvement of reactive oxygen species in urotensin II-induced proliferation of cardiac fibroblasts. Eur J Pharmacol 2008;593:24-9.
6. Tamamori M, Ito H, Hiroe M, Marumo F, Hata RI. Stimulation of collagen synthesis in rat cardiac fibroblasts by exposure to hypoxic culture conditions and suppression of the effect by natriuretic peptides. Cell Biol Int 1997;21:175-80.
7. MacLean MR, Alexander D, Stirrat A, Gallagher M, Douglas SA, Ohlstein EH et al. Contractile response to human urotensin-II in rat and human pulmonary arteries: effect of endothelial factors and chronic hypoxia in the rat. Br J Pharmacol 2000;130:201-4.
8. Zhang Y, Li J, Cao J, Chen J, Yang J, Zhang Z et al. Effect of chronic hypoxia on contents of urotensin II and its functional receptors in rat myocardium. Heart Vessels 2002;16:64-8.
9. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther 2009;123:255-78.
10. Chen J, Mehta JL. Angiotensin II-mediated oxidative stress and procollagen-I expression in cardiac fibroblasts: blockade by pravastatin and pioglitazone. Am J Physiol Heart Circ Physiol 2006;291:H1378-45.
11. Segain JP, Rolli-Derkinderen M, Gervois N, de la Bletiere DR, Loirand G, Pacaud P. Urotensin II is a new chemotactic factor for UT receptor-expressing monocytes. J Immunol 2007;179:9019.
12. Gould PS, Gu M, Liao J, Ahmad S, Cudmore MJ, Ahmed A et al. Upregulation of urotensin II receptor in preeclampsia causes in vitro placental release of soluble vascular endothelial growth factor receptor 1 in hypoxia. Hypertension 2010;56:172-8.
13. Djordjevic T, BelAiba RS, Boncello S, Pfeilschifter J, Hess J, Gorlach A. Human urotensin II is a novel activator of NADPH oxidase in human pulmonary artery smooth muscle cells. Arterioscler Thromb Vasc Biol 2005;25:519-25.
14. Gustafsson AB, Brunton LL. β-Adrenergic stimulation of rat cardiac fibroblasts enhances induction of nitric-oxide synthase by interleukin-1β via message stabilization. Mol Pharmacol 2000;58:1470-8.
15. Shyu KG, Wang BW, Yang YH, Tsai SC, Lin S, Lee CC. Amphetamine activates connexin43 gene expression in cultured neonatal rat cardiomyocytes through JNK and AP-1 pathway. Cardiovasc Res 2004;63:98-108.
16. Chang H, Shyu KG, Wang BW, Kuan P. Regulation of hypoxia-inducible factor 1-α by cyclical mechanical stretch in rat vascular smooth muscle cells. Clin Sci 2003;105:447-56.
17. Shyu KG, Chao YM, Wang BW, Kuan P. Regulation of discoidin domain receptor 2 by cyclic mechanical stretch in cultured rat vascular smooth muscle cells. Hypertension 2005;46:614-21.
18. McLennan HR, Degli Esposti M. The contribution of mitochondrial respiratory complexes to the production of reactive oxygen species. J Bioenegr Biomembr 2000;32:153-62.
19. Tzanidis A, Hannan RD, Thomas WG, Onan D, Autelitano DJ, See F et al. Direct actions of urotensin II on the heart: implications for cardiac fibrosis and hypertrophy. Circ Res 2003;93:246-53.
20. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 2002;359:1990-7.
21. Ng LL, Loke I, O'Brien R, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-80.
22. Khan SQ, Bhandari SS, Quinn P, Davies JE, Ng LL. Urotensin II is raised in acute myocardial infarction and low levels predict risk of adverse clinical outcome in humans. Int J Cardiol 2007;117:323-8.
23. Dai HY, Guo XG, Ge ZM, Li ZH, Yu XJ, Tang MX et al. Elevated expression of urotensin II and its receptor in diabetic cardiomyopathy. J Diabetes Complications 2008;22:137-43.
24. Bousette N, Hu F, Ohlstein EH, Dhanak D, Douglas SA, Giaid A. Urotensin-II blockade with SB-611812 attenuates cardiac dysfunction in a rat model of coronary artery ligation. J Mol Cell Cardiol 2006;41:285-95.
25. Tran L, Kompa AR, Kemp W, Phrommintikul A, Wang BH, Krum H. Chronic urotensin-II infusion induces diastolic dysfunction and enhances collagen production in rats. Am J Physiol Heart Circ Physiol 2010;298:H608-13.
26. Inamoto S, Hayashi T, Tazawa N, Mori T, Yamashita C, Nakano D et al. Angiotensin-II receptor blocker exerts cardioprotection in diabetic rats exposed to hypoxia. Circ J 2006;70:787-92.
27. Seta KA, Millhorn DE. Functional genomics approach to hypoxia signaling. J Appl Physiol 2004;96:765-73.
28. Ohan D, Pipolo L, Yang E, Hannan RD, Thomas WG. Urotensin II promotes hypertrophy of cardiac myocytes via mitogen-activated protein kinases. Mol Endocrinol 2004;18:2344-54.
29. Wang BW, Chang H, Lin S, Kuan P, Shyu KG. Induction of matrix metalloproteinases-14 and-2 by cyclical mechanical stretch is mediated by tumor necrosis factor-α in cultured human umbilical vein endothelial cells. Cardiovasc Res 2003;59:460-9.
30. Fontes-Sousa AP, Pires AL, Monteiro-Cardoso VF, Leite-Moreira AF. Urotensin II-induced increase in myocardial distensibility is modulated by angiotensin II and endothelin-I. Physiol Res 2009;58:653-60.
31. Wang YX, Ding YJ, Zhu YZ, Shi Y, Yao T, Zhu YC. Role of PKC in the novel synergistic action of urotensin II and angiotensin II and in urotensin II-induced vasoconstriction. Am J Physiol Heart Circ Physiol 2007;292:H348-59.
32. Schellings MWM, Vanhoutte D, van Almen GC, Swinnen M, Leenders JJG, Kubben N et al. Syndecan-1 amplifies angiotensin II-induced cardiac fibrosis. Hypertension 2010;55:249-56.
33. Ruperez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 2003;108:1499-505.
34. Chen K, Mehta JL, Li D, Joseph L, Joseph J. Transforming growth factor beta receptor endoglin is expressed in cardiac fibroblasts and modulates profibrotic actions of angiotensin II. Circ Res 2004;95:1167-73.